No Data
No Data
The Tokyo Stock Exchange Gross Market 250 index rebounded significantly, driven by large cap stocks.
Tokyo Stock Exchange Growth Market Index 833.73 +25.69 / Volume 0.2 billion 8.38 million shares / Trading value 116 billion yen; Tokyo Stock Exchange Growth Market 250 Index 653.27 +21.13 / Volume 0.1 billion 40.66 million shares / Trading value 97.9 billion yen. Today's growth market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index recorded significant rebounds. The number of advancing stocks was 484, the number of declining stocks was 74, and unchanged stocks were 22. The U.S. stock market rose on the 11th. The Dow Jones Average was up 124.75 dollars.
Stocks that moved the previous day part1 Edge Technology, R Planner, Prodelight, etc.
Stock name <code> 10-day closing price ⇒ previous day comparison stream <3071> 99 - Downward revision of financial estimates for the fiscal year ending 2025. Appirits <4174> 740 - Downward revision of profit estimates for the fiscal year ending 2025. Canvas <4575> 892 +60 Received patent evaluation from the US Patent Office for IDO/TDO inhibitors. Edge Technology <4268> 737 +100 Continuing movement to the TOB price (841 yen). Earl Planner <2983> 1145 +1
Volume change rate ranking (13:00) - Helios, Kan Kisen, etc. rank in.
※In the volume change rate ranking, by comparing the average volume of the past 5 days with the volume on the day of delivery, you can understand the interest of market participants such as market trends. ■Top volume change rate [September 10, 13:32 current] (comparison of average volume of the past 5 days) Code→Stock→Volume→5-day average volume→Volume change rate→Stock price change rate <6769> Zacta 1630200 236686.58 261.54% 0.2469%<9348>
CANBAS ranked in and received a patent assessment from the Japanese Patent Office for its IDO/TDO inhibitor.
CANBAS <4575> has made it onto the rankings (as of 13:32). The Shizuoka Prefectural University, a joint research partner of the company, announced that it has received a patent assessment from the Japanese Patent Office for the candidate anticancer drug being developed, an IDO/TDO inhibitor, which has become a buying catalyst. Although this patent assessment reception will not have an impact on this fiscal year's performance, it is expected to contribute to the improvement of the company's long-term value, such as the expansion of the drug discovery pipeline.
Individual investor, Yugetsu Yuken: The focus on australian small/mid cap stocks is reviving, drawing even more attention to biotech stocks! [FISCO Social Reporter]
The following is a comment written by individual investor "Yuugentei Tamaki" (Blog: Profitable Stock Information "The Cat's Husband's Ceilingless Stock") of the FISCO Social Reporter. At FISCO, we strive to collaborate with individuals who actively disseminate information in order to provide a wider range of information to investors. ----------- * After the news that the Ministry of Economy, Trade and Industry will compile an action plan to expand the biotechnology industry on September 2, 2024 at 13:00, biotech stocks have a wide range of
Learning Aid, D&M Company, etc.
<184A> Gakumiaeido Co., Ltd. Morgan Stanley MUFG Securities Co., Ltd. Shareholding Ratio - → 5.08% Reporting Obligation Start Date 2024/08/30 <189A> D&M Company Morgan Stanley MUFG Securities Co., Ltd. Shareholding Ratio 5.18% → 0.27% Reporting Obligation Start Date 2024/08/30 <2586> Furutta Furuttaebo Fund (Evo Fund) Shareholding Ratio
No Data
No Data